Loading...
XNASSRDX
Market cap508mUSD
Jan 14, Last price  
35.55USD
1D
-0.81%
1Q
-7.73%
Jan 2017
39.96%
Name

Surmodics Inc

Chart & Performance

D1W1MN
XNAS:SRDX chart
P/E
P/S
4.03
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
0.54%
Rev. gr., 5y
4.73%
Revenues
126m
-4.91%
62,381,00069,884,00073,164,00097,051,000121,534,00069,898,00067,781,00051,928,00056,132,00057,439,00061,898,00071,366,00073,112,00081,336,000100,077,00094,864,000105,136,00099,951,000132,584,000126,078,000
Net income
-12m
L+651.43%
-8,246,00020,334,0003,346,00014,739,00037,550,000-21,089,000-12,778,00010,231,00015,167,00012,031,00013,447,0009,985,0003,926,000-4,457,0007,592,0001,123,0004,237,000-27,274,000-1,536,000-11,542,000
CFO
248k
-97.64%
25,950,00035,279,00050,714,00039,822,00031,321,00022,008,00019,955,00016,112,00017,665,00018,185,00015,021,00025,166,00014,053,00034,052,0008,038,00014,010,00015,389,000-17,223,00010,514,000248,000
Earnings
Jan 30, 2025

Profile

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
IPO date
Mar 04, 1998
Employees
447
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑092023‑092022‑092021‑092020‑092019‑092018‑092017‑092016‑092015‑09
Income
Revenues
126,078
-4.91%
132,584
32.65%
99,951
-4.93%
Cost of revenue
43,026
81,132
126,980
Unusual Expense (Income)
NOPBT
83,052
51,452
(27,029)
NOPBT Margin
65.87%
38.81%
Operating Taxes
4,036
4,023
4,781
Tax Rate
4.86%
7.82%
NOPAT
79,016
47,429
(31,810)
Net income
(11,542)
651.43%
(1,536)
-94.37%
(27,274)
-743.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,216
1,252
125
BB yield
-0.22%
-0.28%
-0.03%
Debt
Debt current
1,040
872
10,000
Long-term debt
35,890
36,225
8,649
Deferred revenue
2,400
5,088
Other long-term liabilities
5,135
5,086
6,930
Net debt
(3,182)
(6,251)
(349)
Cash flow
Cash from operating activities
248
10,514
(17,223)
CAPEX
(3,492)
(2,918)
(3,370)
Cash from investing activities
(2,937)
(6,822)
6,230
Cash from financing activities
(2,950)
18,406
(375)
FCF
77,636
41,550
(33,808)
Balance
Cash
40,112
45,352
18,998
Long term investments
(2,004)
Excess cash
33,808
36,719
14,000
Stockholders' equity
716
83,204
79,618
Invested Capital
156,558
123,928
120,253
ROIC
56.34%
38.85%
ROCE
52.21%
31.63%
EV
Common stock shares outstanding
14,153
14,031
13,916
Price
38.78
20.85%
32.09
5.56%
30.40
-45.32%
Market cap
548,853
21.90%
450,255
6.43%
423,046
-45.61%
EV
545,671
444,004
422,697
EBITDA
91,746
59,974
(17,887)
EV/EBITDA
5.95
7.40
Interest
3,540
3,489
598
Interest/NOPBT
4.26%
6.78%